von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects: The Hoorn Study

Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is uncertain whether vWf and CRP predict mortality in a general population and whether vWf and CRP predict mortality through similar pathways. This study investig...

Full description

Saved in:
Bibliographic Details
Published inArteriosclerosis, thrombosis, and vascular biology Vol. 19; no. 12; p. 3071
Main Authors Jager, Agnes, van Hinsbergh, Victor W. M., Kostense, Piet J., Emeis, Jef J., Yudkin, John S., Nijpels, Giel, Dekker, Jacqueline M., Heine, Robert J., Bouter, Lex M., Stehouwer, Coen D. A.
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Heart Association, Inc 01.12.1999
Hagerstown, MD Lippincott
Subjects
Online AccessGet full text
ISSN1079-5642
1524-4636
DOI10.1161/01.ATV.19.12.3071

Cover

Loading…
Abstract Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is uncertain whether vWf and CRP predict mortality in a general population and whether vWf and CRP predict mortality through similar pathways. This study investigated the association of vWf and CRP with cardiovascular and all-cause mortality among diabetic and nondiabetic subjects. An age-, sex-, and glucose tolerance–stratified sample (n=631) of a population-based cohort aged 50 to 75 years was followed prospectively for 5 years. After 5 years of follow-up, 58 subjects had died (24 of cardiovascular causes). vWf (>1.56 IU/mL) and CRP (>2.84 mg/L) levels in the upper tertile were associated with, respectively, a 3- and 2-fold increase in cardiovascular mortality after adjustment for age, sex, and glucose tolerance status. Analyses in nondiabetic and diabetic subjects separately gave similar results. After further adjustment for hypertension, levels of HDL cholesterol and triglyceride, smoking habits, ischemic heart disease, and peripheral arterial disease, the relative risks (RRs) were 3.0 (95% CI 1.2 to 7.9) for vWf and 1.4 (95% CI 0.6 to 3.5) for CRP. When both vWf and CRP were included in the latter multivariate analysis, the RRs were 3.0 (95% CI 1.1 to 7.9) for vWf and 1.3 (95% CI 0.5 to 3.4) for CRP. The association between vWf and risk of cardiovascular mortality was independent of blood group (O versus non-O) and, moreover, similar among subjects with different blood groups. Repeating the analyses for all-cause mortality gave similar results for CRP. For vWf, the RR was 2.0 (95% CI 1.1 to 3.5) after adjustment for all other risk factors. Increased levels of vWf are independently associated with cardiovascular and all-cause mortality in both diabetic and nondiabetic subjects. The association between increased levels of CRP and cardiovascular mortality was partly explained by other risk factors. Mutual adjustment of vWf and CRP did not markedly change the results, favoring the hypothesis that vWf and CRP predict mortality through different pathways.
AbstractList Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is uncertain whether vWf and CRP predict mortality in a general population and whether vWf and CRP predict mortality through similar pathways. This study investigated the association of vWf and CRP with cardiovascular and all-cause mortality among diabetic and nondiabetic subjects. An age-, sex-, and glucose tolerance–stratified sample (n=631) of a population-based cohort aged 50 to 75 years was followed prospectively for 5 years. After 5 years of follow-up, 58 subjects had died (24 of cardiovascular causes). vWf (>1.56 IU/mL) and CRP (>2.84 mg/L) levels in the upper tertile were associated with, respectively, a 3- and 2-fold increase in cardiovascular mortality after adjustment for age, sex, and glucose tolerance status. Analyses in nondiabetic and diabetic subjects separately gave similar results. After further adjustment for hypertension, levels of HDL cholesterol and triglyceride, smoking habits, ischemic heart disease, and peripheral arterial disease, the relative risks (RRs) were 3.0 (95% CI 1.2 to 7.9) for vWf and 1.4 (95% CI 0.6 to 3.5) for CRP. When both vWf and CRP were included in the latter multivariate analysis, the RRs were 3.0 (95% CI 1.1 to 7.9) for vWf and 1.3 (95% CI 0.5 to 3.4) for CRP. The association between vWf and risk of cardiovascular mortality was independent of blood group (O versus non-O) and, moreover, similar among subjects with different blood groups. Repeating the analyses for all-cause mortality gave similar results for CRP. For vWf, the RR was 2.0 (95% CI 1.1 to 3.5) after adjustment for all other risk factors. Increased levels of vWf are independently associated with cardiovascular and all-cause mortality in both diabetic and nondiabetic subjects. The association between increased levels of CRP and cardiovascular mortality was partly explained by other risk factors. Mutual adjustment of vWf and CRP did not markedly change the results, favoring the hypothesis that vWf and CRP predict mortality through different pathways.
Abstract —Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is uncertain whether vWf and CRP predict mortality in a general population and whether vWf and CRP predict mortality through similar pathways. This study investigated the association of vWf and CRP with cardiovascular and all-cause mortality among diabetic and nondiabetic subjects. An age-, sex-, and glucose tolerance–stratified sample (n=631) of a population-based cohort aged 50 to 75 years was followed prospectively for 5 years. After 5 years of follow-up, 58 subjects had died (24 of cardiovascular causes). vWf (>1.56 IU/mL) and CRP (>2.84 mg/L) levels in the upper tertile were associated with, respectively, a 3- and 2-fold increase in cardiovascular mortality after adjustment for age, sex, and glucose tolerance status. Analyses in nondiabetic and diabetic subjects separately gave similar results. After further adjustment for hypertension, levels of HDL cholesterol and triglyceride, smoking habits, ischemic heart disease, and peripheral arterial disease, the relative risks (RRs) were 3.0 (95% CI 1.2 to 7.9) for vWf and 1.4 (95% CI 0.6 to 3.5) for CRP. When both vWf and CRP were included in the latter multivariate analysis, the RRs were 3.0 (95% CI 1.1 to 7.9) for vWf and 1.3 (95% CI 0.5 to 3.4) for CRP. The association between vWf and risk of cardiovascular mortality was independent of blood group (O versus non-O) and, moreover, similar among subjects with different blood groups. Repeating the analyses for all-cause mortality gave similar results for CRP. For vWf, the RR was 2.0 (95% CI 1.1 to 3.5) after adjustment for all other risk factors. Increased levels of vWf are independently associated with cardiovascular and all-cause mortality in both diabetic and nondiabetic subjects. The association between increased levels of CRP and cardiovascular mortality was partly explained by other risk factors. Mutual adjustment of vWf and CRP did not markedly change the results, favoring the hypothesis that vWf and CRP predict mortality through different pathways.
Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is uncertain whether vWf and CRP predict mortality in a general population and whether vWf and CRP predict mortality through similar pathways. This study investigated the association of vWf and CRP with cardiovascular and all-cause mortality among diabetic and nondiabetic subjects. An age-, sex-, and glucose tolerance-stratified sample (n=631) of a population-based cohort aged 50 to 75 years was followed prospectively for 5 years. After 5 years of follow-up, 58 subjects had died (24 of cardiovascular causes). vWf (>1.56 IU/mL) and CRP (>2.84 mg/L) levels in the upper tertile were associated with, respectively, a 3- and 2-fold increase in cardiovascular mortality after adjustment for age, sex, and glucose tolerance status. Analyses in nondiabetic and diabetic subjects separately gave similar results. After further adjustment for hypertension, levels of HDL cholesterol and triglyceride, smoking habits, ischemic heart disease, and peripheral arterial disease, the relative risks (RRs) were 3.0 (95% CI 1.2 to 7.9) for vWf and 1.4 (95% CI 0.6 to 3.5) for CRP. When both vWf and CRP were included in the latter multivariate analysis, the RRs were 3.0 (95% CI 1.1 to 7.9) for vWf and 1.3 (95% CI 0.5 to 3.4) for CRP. The association between vWf and risk of cardiovascular mortality was independent of blood group (O versus non-O) and, moreover, similar among subjects with different blood groups. Repeating the analyses for all-cause mortality gave similar results for CRP. For vWf, the RR was 2.0 (95% CI 1.1 to 3.5) after adjustment for all other risk factors. Increased levels of vWf are independently associated with cardiovascular and all-cause mortality in both diabetic and nondiabetic subjects. The association between increased levels of CRP and cardiovascular mortality was partly explained by other risk factors. Mutual adjustment of vWf and CRP did not markedly change the results, favoring the hypothesis that vWf and CRP predict mortality through different pathways.Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is uncertain whether vWf and CRP predict mortality in a general population and whether vWf and CRP predict mortality through similar pathways. This study investigated the association of vWf and CRP with cardiovascular and all-cause mortality among diabetic and nondiabetic subjects. An age-, sex-, and glucose tolerance-stratified sample (n=631) of a population-based cohort aged 50 to 75 years was followed prospectively for 5 years. After 5 years of follow-up, 58 subjects had died (24 of cardiovascular causes). vWf (>1.56 IU/mL) and CRP (>2.84 mg/L) levels in the upper tertile were associated with, respectively, a 3- and 2-fold increase in cardiovascular mortality after adjustment for age, sex, and glucose tolerance status. Analyses in nondiabetic and diabetic subjects separately gave similar results. After further adjustment for hypertension, levels of HDL cholesterol and triglyceride, smoking habits, ischemic heart disease, and peripheral arterial disease, the relative risks (RRs) were 3.0 (95% CI 1.2 to 7.9) for vWf and 1.4 (95% CI 0.6 to 3.5) for CRP. When both vWf and CRP were included in the latter multivariate analysis, the RRs were 3.0 (95% CI 1.1 to 7.9) for vWf and 1.3 (95% CI 0.5 to 3.4) for CRP. The association between vWf and risk of cardiovascular mortality was independent of blood group (O versus non-O) and, moreover, similar among subjects with different blood groups. Repeating the analyses for all-cause mortality gave similar results for CRP. For vWf, the RR was 2.0 (95% CI 1.1 to 3.5) after adjustment for all other risk factors. Increased levels of vWf are independently associated with cardiovascular and all-cause mortality in both diabetic and nondiabetic subjects. The association between increased levels of CRP and cardiovascular mortality was partly explained by other risk factors. Mutual adjustment of vWf and CRP did not markedly change the results, favoring the hypothesis that vWf and CRP predict mortality through different pathways.
Author Jager, Agnes
Dekker, Jacqueline M.
Kostense, Piet J.
Nijpels, Giel
van Hinsbergh, Victor W. M.
Bouter, Lex M.
Emeis, Jef J.
Yudkin, John S.
Heine, Robert J.
Stehouwer, Coen D. A.
AuthorAffiliation From the Institute for Research in Extramural Medicine (A.J., P.J.K., G.N., J.M.D., R.J.H., L.M.B., C.D.A.S.), the Institute for Cardiovascular Research (V.W.M.v.H., C.D.A.S.), and the Department of Epidemiology and Biostatistics (P.J.K., L.M.B.), Vrije Universiteit, Amsterdam, Netherlands; Gaubius Laboratory (V.W.M.v.H., J.J.E.), TNO Prevention and Health, Leiden, the Netherlands; the Centre for Diabetes and Cardiovascular Risk (J.S.Y.), Department of Medicine, University College London Medical School, London, UK; and the Department of Internal Medicine (R.J.H., C.D.A.S.), University Hospital Vrije Universiteit, Amsterdam, the Netherlands
AuthorAffiliation_xml – name: From the Institute for Research in Extramural Medicine (A.J., P.J.K., G.N., J.M.D., R.J.H., L.M.B., C.D.A.S.), the Institute for Cardiovascular Research (V.W.M.v.H., C.D.A.S.), and the Department of Epidemiology and Biostatistics (P.J.K., L.M.B.), Vrije Universiteit, Amsterdam, Netherlands; Gaubius Laboratory (V.W.M.v.H., J.J.E.), TNO Prevention and Health, Leiden, the Netherlands; the Centre for Diabetes and Cardiovascular Risk (J.S.Y.), Department of Medicine, University College London Medical School, London, UK; and the Department of Internal Medicine (R.J.H., C.D.A.S.), University Hospital Vrije Universiteit, Amsterdam, the Netherlands
Author_xml – sequence: 1
  givenname: Agnes
  surname: Jager
  fullname: Jager, Agnes
  organization: From the Institute for Research in Extramural Medicine (A.J., P.J.K., G.N., J.M.D., R.J.H., L.M.B., C.D.A.S.), the Institute for Cardiovascular Research (V.W.M.v.H., C.D.A.S.), and the Department of Epidemiology and Biostatistics (P.J.K., L.M.B.), Vrije Universiteit, Amsterdam, Netherlands; Gaubius Laboratory (V.W.M.v.H., J.J.E.), TNO Prevention and Health, Leiden, the Netherlands; the Centre for Diabetes and Cardiovascular Risk (J.S.Y.), Department of Medicine, University College London Medical School, London, UK; and the Department of Internal Medicine (R.J.H., C.D.A.S.), University Hospital Vrije Universiteit, Amsterdam, the Netherlands
– sequence: 2
  givenname: Victor
  surname: van Hinsbergh
  middlename: W. M.
  fullname: van Hinsbergh, Victor W. M.
– sequence: 3
  givenname: Piet
  surname: Kostense
  middlename: J.
  fullname: Kostense, Piet J.
– sequence: 4
  givenname: Jef
  surname: Emeis
  middlename: J.
  fullname: Emeis, Jef J.
– sequence: 5
  givenname: John
  surname: Yudkin
  middlename: S.
  fullname: Yudkin, John S.
– sequence: 6
  givenname: Giel
  surname: Nijpels
  fullname: Nijpels, Giel
– sequence: 7
  givenname: Jacqueline
  surname: Dekker
  middlename: M.
  fullname: Dekker, Jacqueline M.
– sequence: 8
  givenname: Robert
  surname: Heine
  middlename: J.
  fullname: Heine, Robert J.
– sequence: 9
  givenname: Lex
  surname: Bouter
  middlename: M.
  fullname: Bouter, Lex M.
– sequence: 10
  givenname: Coen
  surname: Stehouwer
  middlename: D. A.
  fullname: Stehouwer, Coen D. A.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1210292$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/10591689$$D View this record in MEDLINE/PubMed
BookMark eNp1kl1rFDEUhgep2A_9Ad7IIOJVZ81JMpmNd2W1Vqgf2FXxKmQyZ9ms2aQmmZb992bdLYWCFyHnkOc9HN43x9WBDx6r6jmQCYCANwQmZ_MfE5AToBNGOnhUHUFLecMFEwelJp1sWsHpYXWc0ooQwiklT6pDIK0EMZVH1XgTfP3TOod91H6oz7XJIZ7Ws-YbltLeYP01hozWn9bb97b5hTrWn0LM2tm8qa2v31ndY7bmH_A5-OGuvxr7FZqc3tbzJdYXIURfX-Vx2DytHi-0S_hsf59U38_fz2cXzeWXDx9nZ5eN4azlDSw4MOQEQNOhbcvuQ0cG3XLWa64lkXxAMRUL3qOhgzBM4FR2AkyPVEgY2En1ejf3OoY_I6as1jYZdE57DGNSQjIuBYgCvnwArsIYfdlN0WKaZN10C73YQ2O_xkFdR7vWcaPu3CzAqz2gk9FuURw1Nt1zFAiVtGDdDjMxpBRxoYzNOtvgc9TWlXlqG68ioEq8CmRRqm28RQkPlPc7_F_Dd5rb4DLG9NuNtxjVErXLS7X9E0yQtgEpJdDSNuUwzv4CyGu0kA
CODEN ATVBFA
CitedBy_id crossref_primary_10_3389_fcvm_2022_976817
crossref_primary_10_1046_j_1365_2796_2000_00754_x
crossref_primary_10_1016_j_diabres_2004_05_009
crossref_primary_10_18214_jkaem_2009_11_1_7
crossref_primary_10_3346_jkms_2008_23_1_77
crossref_primary_10_1016_S0021_9150_03_00050_9
crossref_primary_10_1093_ndt_gfh680
crossref_primary_10_1016_S0002_9149_02_02556_0
crossref_primary_10_5694_mja2_50239
crossref_primary_10_1046_j_1365_2796_2003_01156_x
crossref_primary_10_1182_blood_2004_01_0107
crossref_primary_10_1371_journal_pmed_1000099
crossref_primary_10_1155_2017_5620314
crossref_primary_10_1046_j_0954_6820_2003_01246_x
crossref_primary_10_1007_s12185_012_1041_x
crossref_primary_10_1161_ATVBAHA_113_301359
crossref_primary_10_1016_j_cca_2007_03_007
crossref_primary_10_1016_S0021_9150_02_00371_4
crossref_primary_10_1111_vox_12786
crossref_primary_10_1016_j_ejim_2008_07_008
crossref_primary_10_3132_dvdr_2007_007
crossref_primary_10_2337_diabetes_53_6_1570
crossref_primary_10_1373_clinchem_2007_100271
crossref_primary_10_1373_clinchem_2008_115923
crossref_primary_10_1097_00041433_200010000_00010
crossref_primary_10_1016_j_thromres_2008_02_003
crossref_primary_10_1111_j_1538_7836_2005_01369_x
crossref_primary_10_1111_j_1365_2796_2007_01770_x
crossref_primary_10_1111_j_1538_7836_2004_00965_x
crossref_primary_10_1111_j_1365_2796_2008_02015_x
crossref_primary_10_1016_j_cca_2005_12_030
crossref_primary_10_2337_db06_0116
crossref_primary_10_1186_1758_5996_6_32
crossref_primary_10_2337_dc06_1747
crossref_primary_10_1016_S1575_0922_03_74506_9
crossref_primary_10_1016_j_cjca_2017_10_017
crossref_primary_10_2337_diacare_29_02_06_dc05_1700
crossref_primary_10_2337_diacare_25_8_1371
crossref_primary_10_1111_j_1365_2265_2011_04190_x
crossref_primary_10_1210_jc_2008_2534
crossref_primary_10_3899_jrheum_090699
crossref_primary_10_1111_j_1399_5618_2009_00757_x
crossref_primary_10_1097_MBC_0b013e3282f54522
crossref_primary_10_15407_internalmed2020_01_043
crossref_primary_10_1016_j_atherosclerosis_2004_01_002
crossref_primary_10_1097_01_hjh_0000217841_34595_59
crossref_primary_10_3389_fmed_2020_00543
crossref_primary_10_1016_j_cjca_2022_02_002
crossref_primary_10_1007_s10787_014_0212_1
crossref_primary_10_1016_j_atherosclerosis_2014_06_004
crossref_primary_10_1093_ije_dyv205
crossref_primary_10_1097_MD_0000000000001708
crossref_primary_10_1155_2012_481840
crossref_primary_10_1084_jem_20080130
crossref_primary_10_3945_jn_111_139733
crossref_primary_10_1002_alz_14272
crossref_primary_10_1016_j_ijcard_2011_06_088
crossref_primary_10_1046_j_1464_5491_2001_00416_x
crossref_primary_10_1016_j_thromres_2010_01_031
crossref_primary_10_1093_ndt_16_10_2028
crossref_primary_10_3109_08958378_2011_593587
crossref_primary_10_1177_1076029607305115
crossref_primary_10_1289_ehp_7938
crossref_primary_10_1016_j_cca_2005_12_027
crossref_primary_10_2337_diabetes_52_2_442
crossref_primary_10_51248__v42i1_594
crossref_primary_10_1046_j_1467_789X_2002_00056_x
crossref_primary_10_3945_jn_114_201236
crossref_primary_10_1016_j_atherosclerosis_2017_01_005
crossref_primary_10_1002_ajmg_b_30824
crossref_primary_10_1586_erc_09_184
crossref_primary_10_1056_NEJMoa032804
crossref_primary_10_1016_j_diabres_2014_04_006
crossref_primary_10_1373_49_4_669
crossref_primary_10_1007_s11033_014_3026_8
crossref_primary_10_1007_BF02913314
crossref_primary_10_1161_HYPERTENSIONAHA_111_174557
crossref_primary_10_1016_j_cca_2011_07_030
crossref_primary_10_1007_s11428_008_0252_5
crossref_primary_10_1016_S0002_9149_03_00657_X
crossref_primary_10_1373_clinchem_2007_099465
crossref_primary_10_1053_j_seminhematol_2004_09_009
crossref_primary_10_1309_LM0XULJ3JAYARH9K
crossref_primary_10_3923_pjbs_2005_1383_1386
crossref_primary_10_1111_dom_13136
crossref_primary_10_1007_BF03345357
crossref_primary_10_1080_10408360600966753
crossref_primary_10_1111_j_1538_7836_2006_01949_x
crossref_primary_10_1507_endocrj_52_89
crossref_primary_10_3747_pdi_2012_00004
crossref_primary_10_1080_10641963_2021_1896729
crossref_primary_10_2337_ds18_0002
crossref_primary_10_3390_ijms21207804
crossref_primary_10_1093_eurheartj_ehi104
crossref_primary_10_1038_sj_jhh_1001812
crossref_primary_10_1515_jpem_2010_126
crossref_primary_10_1111_j_1538_7836_2005_01305_x
crossref_primary_10_1002_clc_20681
crossref_primary_10_1111_j_1600_0609_2006_00656_x
crossref_primary_10_1111_j_1538_7836_2005_01694_x
crossref_primary_10_1111_j_1365_2796_2004_01350_x
crossref_primary_10_1097_HJH_0b013e328350a487
crossref_primary_10_2337_diacare_26_7_2165
crossref_primary_10_1160_th14_05_0457
crossref_primary_10_1046_j_1365_2796_2002_01024_x
crossref_primary_10_1007_s00125_015_3586_8
crossref_primary_10_1530_JME_13_0079
crossref_primary_10_1007_s00394_017_1420_4
crossref_primary_10_1097_MD_0000000000011269
crossref_primary_10_1007_s00441_008_0685_6
crossref_primary_10_1002_dmrr_2406
crossref_primary_10_1093_ndt_gfr735
crossref_primary_10_1007_BF02981972
crossref_primary_10_1016_j_amjmed_2005_06_057
crossref_primary_10_1093_ndt_16_3_529
crossref_primary_10_1093_ckj_sfz076
crossref_primary_10_1007_s11239_012_0682_1
crossref_primary_10_1053_j_seminhematol_2004_11_001
crossref_primary_10_1093_clinchem_48_10_1781
crossref_primary_10_1016_S1056_8727_02_00184_8
crossref_primary_10_1046_j_1464_5491_2002_00808_x
crossref_primary_10_1093_ndt_16_7_1442
crossref_primary_10_1038_s41598_017_07029_7
crossref_primary_10_2217_bmm_11_108
crossref_primary_10_1111_j_1538_7836_2005_01279_x
crossref_primary_10_1111_j_1464_5491_2004_01388_x
crossref_primary_10_1038_ncpcardio1322
crossref_primary_10_1007_s00125_007_0905_8
crossref_primary_10_1007_s00421_020_04419_0
crossref_primary_10_1002_eji_201646386
crossref_primary_10_1016_j_jdiacomp_2019_107413
crossref_primary_10_1007_s11892_013_0380_1
crossref_primary_10_1007_s13410_016_0479_4
crossref_primary_10_1111_j_1747_4949_2010_00420_x
crossref_primary_10_1097_00019501_200109000_00003
crossref_primary_10_1073_pnas_242407999
crossref_primary_10_1016_j_jstrokecerebrovasdis_2024_108044
crossref_primary_10_1016_j_jacl_2013_04_004
crossref_primary_10_1016_S0021_9150_03_00198_9
crossref_primary_10_1007_s12603_020_1385_5
crossref_primary_10_1093_ndt_gfg080
crossref_primary_10_1590_S0004_27302008000200030
crossref_primary_10_1016_j_thromres_2011_07_033
crossref_primary_10_1161_JAHA_116_004554
crossref_primary_10_3389_fcvm_2022_1038030
crossref_primary_10_1111_j_1523_1755_2002_kid571_x
crossref_primary_10_1111_j_1538_7836_2005_01571_x
crossref_primary_10_1046_j_1365_2141_2003_04776_x
crossref_primary_10_1186_s12916_014_0237_8
crossref_primary_10_1007_s11892_002_0052_z
crossref_primary_10_1016_S0021_9150_01_00626_8
crossref_primary_10_1067_mhj_2002_124054
crossref_primary_10_2337_diacare_28_6_1383
crossref_primary_10_1016_j_mehy_2012_12_035
crossref_primary_10_1002_ptr_6707
crossref_primary_10_1016_j_diabres_2007_10_002
crossref_primary_10_1111_j_1462_8902_2004_00340_x
crossref_primary_10_1097_00001573_200207000_00001
crossref_primary_10_1016_j_pcad_2004_02_003
crossref_primary_10_1111_j_1538_7836_2005_01763_x
crossref_primary_10_1097_00004872_200209000_00017
crossref_primary_10_1146_annurev_med_53_082901_103904
crossref_primary_10_1016_S0021_9150_02_00316_7
crossref_primary_10_1093_rheumatology_ken206
crossref_primary_10_1186_s13098_017_0225_1
crossref_primary_10_1016_j_diabres_2007_01_025
crossref_primary_10_1007_s00125_005_1799_y
crossref_primary_10_1007_s00277_006_0085_5
crossref_primary_10_1046_j_1365_2362_2002_01090_x
crossref_primary_10_1042_CS20050025
crossref_primary_10_1161_CIRCULATIONAHA_115_017563
crossref_primary_10_1046_j_1365_2362_2002_00919_x
crossref_primary_10_2337_diabetes_51_4_1157
crossref_primary_10_1016_S0002_9149_03_00504_6
crossref_primary_10_1016_S0735_1097_02_02565_2
crossref_primary_10_1200_JCO_2002_20_13_3042
crossref_primary_10_1016_j_jdiacomp_2006_10_004
crossref_primary_10_1016_S1537_1891_02_00295_1
crossref_primary_10_1016_j_cyto_2019_02_005
crossref_primary_10_2337_dc11_1588
crossref_primary_10_1016_j_atherosclerosis_2008_08_042
crossref_primary_10_1016_j_envres_2005_03_011
crossref_primary_10_1530_EJE_07_0470
crossref_primary_10_1111_joim_12128
crossref_primary_10_1016_j_atherosclerosis_2013_12_002
crossref_primary_10_1080_00365510152379058
crossref_primary_10_1097_MOL_0b013e32832ac03e
crossref_primary_10_1007_s13410_015_0389_x
crossref_primary_10_1007_s11560_022_00590_x
crossref_primary_10_1186_1743_8977_6_25
crossref_primary_10_1586_eem_09_44
crossref_primary_10_1177_1358863X15622281
crossref_primary_10_1017_S0033291713002043
crossref_primary_10_1093_ndt_gfh015
crossref_primary_10_1007_s00125_004_1491_7
crossref_primary_10_1210_jc_2004_0616
crossref_primary_10_1016_j_metabol_2006_06_024
Cites_doi 10.3109/00365518709168882
10.1093/clinchem/18.6.499
10.1056/NEJM199408183310709
10.1161/circ.98.21.2241
10.1161/atvb.17.11.3321
10.1055/s-0038-1656120
10.1056/NEJM199408183310701
10.1136/bmj.311.7017.1405
10.1161/circ.88.3.8353913
10.1161/atvb.17.6.1121
10.1136/hrt.55.1.58
10.1161/atv91.12.9.1525121
10.1056/NEJM198907203210301
10.1182/blood.V93.2.564
10.1161/atvb.18.2.323
10.1172/JCI119561
10.1056/NEJM199704033361401
10.1161/circ.94.9.2057
10.1136/bmj.311.7007.711
10.1016/S0008-6363(96)00272-6
10.1016/S0021-9150(97)00081-6
10.1161/atvb.17.10.2167
10.1016/S0140-6736(96)07591-5
10.2337/diabetes.47.6.859
10.1161/circ.98.4.294
10.1136/bmj.312.7038.1061
10.1093/oxfordjournals.aje.a008963
10.1016/0049-3848(89)90317-4
10.1161/circ.97.20.2007
10.1161/circ.98.8.731
10.1161/atvb.19.3.617
10.1007/s001250050612
10.1007/BF00274216
10.1007/s001250050822
10.1016/0049-3848(96)00021-7
10.1161/atvb.18.9.1359
10.1016/0140-6736(93)91288-W
10.1161/circ.89.3.8124825
10.1016/0024-3205(89)90613-9
10.1056/NEJM198512193132501
10.1016/0140-6736(92)91401-S
10.1007/BF02369357
10.1046/j.1365-2362.1997.2180766.x
10.1038/362801a0
10.1056/NEJM199503093321003
10.1111/j.1365-2141.1994.tb05079.x
10.1161/circ.96.4.1102
10.1007/BF00403180
10.1136/hrt.66.5.351
ContentType Journal Article
Copyright 1999 American Heart Association, Inc.
2000 INIST-CNRS
Copyright American Heart Association, Inc. Dec 1999
Copyright_xml – notice: 1999 American Heart Association, Inc.
– notice: 2000 INIST-CNRS
– notice: Copyright American Heart Association, Inc. Dec 1999
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
K9.
7X8
DOI 10.1161/01.ATV.19.12.3071
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitleList
CrossRef
MEDLINE - Academic
MEDLINE
ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1524-4636
EndPage 3071
ExternalDocumentID 47772086
10591689
1210292
10_1161_01_ATV_19_12_3071
00043605-199912000-00034
Genre Research Support, Non-U.S. Gov't
Journal Article
Comparative Study
GroupedDBID ---
.3C
.55
.GJ
.Z2
01R
0R~
1J1
23N
2WC
3O-
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
71W
77Y
7O~
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAMOA
AAMTA
AAQKA
AARTV
AASCR
AASOK
AAXQO
ABASU
ABBUW
ABDIG
ABJNI
ABPXF
ABQRW
ABVCZ
ABXVJ
ABZAD
ABZZY
ACCJW
ACDDN
ACEWG
ACGFS
ACGOD
ACILI
ACLDA
ACPRK
ACWDW
ACWRI
ACXJB
ACXNZ
ACZKN
ADBBV
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AE6
AEETU
AENEX
AFBFQ
AFDTB
AFFNX
AFUWQ
AGINI
AHJKT
AHMBA
AHOMT
AHQNM
AHRYX
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
AYCSE
BAWUL
BOYCO
BQLVK
BS7
C1A
C45
CS3
DIK
DIWNM
DUNZO
E.X
E3Z
EBS
EEVPB
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FRP
FW0
GNXGY
GQDEL
GX1
H0~
H13
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
J5H
JF9
JG8
JK3
JK8
K8S
KD2
KMI
KQ8
L-C
L7B
N9A
N~7
N~B
N~M
O9-
OAG
OAH
OB2
OCUKA
ODA
OL1
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
PQQKQ
PZZ
RAH
RIG
RLZ
S4R
S4S
T8P
TEORI
TR2
TSPGW
V2I
VVN
W3M
W8F
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YFH
ZGI
ZZMQN
AAYXX
ADGHP
CITATION
IQODW
ADSXY
CGR
CUY
CVF
ECM
EIF
NPM
K9.
7X8
ID FETCH-LOGICAL-c4354-1f413e4011a2d55220d70da543ba4a9094de686f4bec2d6c36e89761cbe2691d3
ISSN 1079-5642
IngestDate Fri Jul 11 11:47:46 EDT 2025
Wed Aug 13 05:44:05 EDT 2025
Mon Aug 18 09:42:53 EDT 2025
Mon Jul 21 09:14:50 EDT 2025
Tue Jul 01 02:21:39 EDT 2025
Thu Apr 24 22:53:08 EDT 2025
Fri May 16 03:46:45 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords Endocrinopathy
Human
Prognosis
Diabetes mellitus
Mortality
Cardiovascular disease
Thrombosis
Vascular disease
Follow up study
Atherosclerosis
Risk factor
Willebrand factor
C reactive protein
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c4354-1f413e4011a2d55220d70da543ba4a9094de686f4bec2d6c36e89761cbe2691d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
PMID 10591689
PQID 204293786
PQPubID 49288
PageCount 1
ParticipantIDs proquest_miscellaneous_69349616
proquest_journals_204293786
pubmed_primary_10591689
pascalfrancis_primary_1210292
crossref_citationtrail_10_1161_01_ATV_19_12_3071
crossref_primary_10_1161_01_ATV_19_12_3071
wolterskluwer_health_00043605-199912000-00034
ProviderPackageCode CITATION
AAYXX
PublicationCentury 1900
PublicationDate 1999-December
PublicationDateYYYYMMDD 1999-12-01
PublicationDate_xml – month: 12
  year: 1999
  text: 1999-December
PublicationDecade 1990
PublicationPlace Philadelphia, PA
Hagerstown, MD
PublicationPlace_xml – name: Philadelphia, PA
– name: Hagerstown, MD
– name: United States
– name: Hagerstown
PublicationTitle Arteriosclerosis, thrombosis, and vascular biology
PublicationTitleAlternate Arterioscler Thromb Vasc Biol
PublicationYear 1999
Publisher American Heart Association, Inc
Lippincott
Publisher_xml – name: American Heart Association, Inc
– name: Lippincott
References e_1_3_2_26_2
e_1_3_2_49_2
e_1_3_2_28_2
e_1_3_2_41_2
e_1_3_2_20_2
e_1_3_2_22_2
e_1_3_2_45_2
e_1_3_2_24_2
e_1_3_2_47_2
e_1_3_2_9_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_18_2
e_1_3_2_39_2
e_1_3_2_54_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_52_2
e_1_3_2_5_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_3_2
e_1_3_2_14_2
e_1_3_2_35_2
e_1_3_2_50_2
e_1_3_2_27_2
e_1_3_2_29_2
e_1_3_2_40_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_23_2
e_1_3_2_44_2
e_1_3_2_25_2
e_1_3_2_46_2
(e_1_3_2_48_2) 1990; 115
(e_1_3_2_43_2) 1999; 93
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_17_2
e_1_3_2_6_2
(e_1_3_2_1_2) 1988; 58
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_53_2
e_1_3_2_32_2
e_1_3_2_51_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_4_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_2_2
References_xml – ident: e_1_3_2_30_2
  doi: 10.3109/00365518709168882
– ident: e_1_3_2_32_2
  doi: 10.1093/clinchem/18.6.499
– ident: e_1_3_2_3_2
  doi: 10.1056/NEJM199408183310709
– ident: e_1_3_2_39_2
  doi: 10.1161/circ.98.21.2241
– volume: 58
  start-page: 249
  year: 1988
  ident: e_1_3_2_1_2
  publication-title: Lab Invest
– ident: e_1_3_2_13_2
  doi: 10.1161/atvb.17.11.3321
– ident: e_1_3_2_7_2
  doi: 10.1055/s-0038-1656120
– ident: e_1_3_2_14_2
  doi: 10.1056/NEJM199408183310701
– ident: e_1_3_2_20_2
  doi: 10.1136/bmj.311.7017.1405
– ident: e_1_3_2_28_2
  doi: 10.1161/circ.88.3.8353913
– ident: e_1_3_2_16_2
  doi: 10.1161/atvb.17.6.1121
– ident: e_1_3_2_53_2
  doi: 10.1136/hrt.55.1.58
– ident: e_1_3_2_11_2
  doi: 10.1161/atv91.12.9.1525121
– ident: e_1_3_2_54_2
  doi: 10.1056/NEJM198907203210301
– ident: e_1_3_2_33_2
– volume: 93
  start-page: 564
  year: 1999
  ident: e_1_3_2_43_2
  publication-title: Blood
  doi: 10.1182/blood.V93.2.564
– ident: e_1_3_2_42_2
  doi: 10.1161/atvb.18.2.323
– ident: e_1_3_2_46_2
  doi: 10.1172/JCI119561
– ident: e_1_3_2_18_2
  doi: 10.1056/NEJM199704033361401
– ident: e_1_3_2_41_2
  doi: 10.1161/circ.94.9.2057
– ident: e_1_3_2_45_2
  doi: 10.1136/bmj.311.7007.711
– ident: e_1_3_2_5_2
  doi: 10.1016/S0008-6363(96)00272-6
– ident: e_1_3_2_10_2
  doi: 10.1016/S0021-9150(97)00081-6
– ident: e_1_3_2_49_2
  doi: 10.1161/atvb.17.10.2167
– ident: e_1_3_2_15_2
  doi: 10.1016/S0140-6736(96)07591-5
– ident: e_1_3_2_52_2
  doi: 10.2337/diabetes.47.6.859
– ident: e_1_3_2_44_2
  doi: 10.1161/circ.98.4.294
– ident: e_1_3_2_51_2
  doi: 10.1136/bmj.312.7038.1061
– ident: e_1_3_2_17_2
  doi: 10.1093/oxfordjournals.aje.a008963
– ident: e_1_3_2_40_2
  doi: 10.1016/0049-3848(89)90317-4
– ident: e_1_3_2_50_2
  doi: 10.1161/circ.97.20.2007
– ident: e_1_3_2_19_2
  doi: 10.1161/circ.98.8.731
– ident: e_1_3_2_26_2
  doi: 10.1161/atvb.19.3.617
– ident: e_1_3_2_21_2
  doi: 10.1007/s001250050612
– volume: 115
  start-page: 339
  year: 1990
  ident: e_1_3_2_48_2
  publication-title: J Lab Clin Med
– ident: e_1_3_2_23_2
  doi: 10.1007/BF00274216
– ident: e_1_3_2_29_2
– ident: e_1_3_2_22_2
  doi: 10.1007/s001250050822
– ident: e_1_3_2_31_2
  doi: 10.1016/0049-3848(96)00021-7
– ident: e_1_3_2_4_2
  doi: 10.1161/atvb.18.9.1359
– ident: e_1_3_2_37_2
  doi: 10.1016/0140-6736(93)91288-W
– ident: e_1_3_2_34_2
  doi: 10.1161/circ.89.3.8124825
– ident: e_1_3_2_47_2
  doi: 10.1016/0024-3205(89)90613-9
– ident: e_1_3_2_38_2
  doi: 10.1056/NEJM198512193132501
– ident: e_1_3_2_24_2
  doi: 10.1016/0140-6736(92)91401-S
– ident: e_1_3_2_27_2
– ident: e_1_3_2_25_2
  doi: 10.1007/BF02369357
– ident: e_1_3_2_6_2
  doi: 10.1046/j.1365-2362.1997.2180766.x
– ident: e_1_3_2_2_2
  doi: 10.1038/362801a0
– ident: e_1_3_2_8_2
  doi: 10.1056/NEJM199503093321003
– ident: e_1_3_2_36_2
  doi: 10.1111/j.1365-2141.1994.tb05079.x
– ident: e_1_3_2_12_2
  doi: 10.1161/circ.96.4.1102
– ident: e_1_3_2_35_2
  doi: 10.1007/BF00403180
– ident: e_1_3_2_9_2
  doi: 10.1136/hrt.66.5.351
SSID ssj0004220
Score 2.139917
Snippet Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is uncertain whether...
Abstract —Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is...
SourceID proquest
pubmed
pascalfrancis
crossref
wolterskluwer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 3071
SubjectTerms Acute-Phase Reaction - metabolism
Aged
Atherosclerosis (general aspects, experimental research)
Biological and medical sciences
Blood and lymphatic vessels
C-Reactive Protein - metabolism
Cardiology. Vascular system
Cohort Studies
Coronary Disease - metabolism
Coronary Disease - mortality
Diabetes Mellitus, Type 2 - metabolism
Diabetes Mellitus, Type 2 - mortality
Female
Follow-Up Studies
Humans
Male
Medical sciences
Middle Aged
Prospective Studies
Risk Factors
Survival Analysis
von Willebrand Factor - metabolism
Title von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects: The Hoorn Study
URI https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00043605-199912000-00034
https://www.ncbi.nlm.nih.gov/pubmed/10591689
https://www.proquest.com/docview/204293786
https://www.proquest.com/docview/69349616
Volume 19
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkBASQnxTxsAPPLGlxI7jxrxVaKjaNARSN-0tyocjVbRJtbQg-Ff4Z7mznTQZBQEvUeM4dpT79XI-3_2OkFdKhDmypnhKFtoTTAdeBGaGx2Xg5zJlQhuy6rMPcnouTi7Dy8HgRydqabNOR9n3nXkl_yNVaAO5YpbsP0i2HRQa4DfIF44gYTj-lYy_VCbqZYGbv2XuaucY16cHtqDRZIeGiMESBWCf0PuG1D1LY3WjBY7RsMb_6ohby6psz-tNim6augn-mFbVVWlCD3ubwRMMC51XNTwdfHMtaQGWX1imzRkO3Ma8Ot6nNnYHWTR6XlVMqZrOyxpDz4zX5-Kw9QSdYlJKaatBftzuaR0vtZ3pxLXlLrNPdYJCrO71x8oLpegrZ9UFIe-oWlBObPc3QDKT1zCazC5GTKG393pfeG2rpQEFmpdM2ipG14i3m0s3yE0OaxAsj3H6qUNFz7mlunBP7bbMYfY3v8yN1LRutJ79c2cFrz5ZFLaGyq5FDvT5WmHcRP3ZpE10jJ_ZPXLXrVroxELwPhno8gG5debiMh6SDSCRbpFILRKP6BaH1OHwiOJ1i0LaopDOS9qgznTooJA2KHxLAYPUYJAaDD4i5--PZ--mnivo4WVglQuPFWAyaVjRs4TnIVj-fj728yQUQZqIRPlK5FpGshCgWHgus0BqUBySZanmUrE8eEz2YH79lNBMZioLojyVPBFFpKNAJqoQQa7H40Il0ZD4zWuOM8d2j0VXFrFZ9UoW-ywGIcVMxYzHKKQhed3esrJUL3_qfNCT3fYO9KEoPiT7jSxjpzHqmKP1F4wjOSQv26ugznGPLil1taljqbCCA4MeTywAOo9iATQkXg8RsU2Yjs2mvkReYVzzNYwRgXj225H2ye3t__A52VtfbfQBmNjr9IWB-k9A5soL
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=von+Willebrand+factor%2C+C-reactive+protein%2C+and+5-year+mortality+in+diabetic+and+nondiabetic+subjects%3A+the+Hoorn+Study&rft.jtitle=Arteriosclerosis%2C+thrombosis%2C+and+vascular+biology&rft.au=Jager%2C+A&rft.au=van+Hinsbergh%2C+V+W&rft.au=Kostense%2C+P+J&rft.au=Emeis%2C+J+J&rft.date=1999-12-01&rft.issn=1079-5642&rft.volume=19&rft.issue=12&rft.spage=3071&rft_id=info:doi/10.1161%2F01.ATV.19.12.3071&rft_id=info%3Apmid%2F10591689&rft.externalDocID=10591689
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-5642&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-5642&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-5642&client=summon